MorphoSys Aktie

40,30EUR
+1,68EUR
+4,35%
21.10.2021

WKN: 663200 / ISIN: DE0006632003

  Kaufen  
Verkaufen
oder
Werbung

MorphoSys Aktien News

04.09.19DGAP-PVR: MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group)
22.08.19DGAP-PVR: MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group)
22.08.19DGAP-PVR: MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group)
19.08.19DGAP-PVR: MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group)
06.08.19DGAP-News: MorphoSys AG Reports Second Quarter 2019 Financial Results (EQS Group)
06.08.19DGAP-News: MorphoSys Discloses Biomarker to Stratify Patient Population in B-MIND Study of Tafasitamab plus Bendamustine in r/r DLBCL (EQS Group)
06.08.19DGAP-News: MorphoSys Announces Intention to Submit Marketing Authorization Application for Tafasitamab to European Medicines Agency (EQS Group)
02.08.19DGAP-PVR: MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group)
02.08.19DGAP-PVR: MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group)
31.07.19DGAP-PVR: MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group)
29.07.19DGAP-PVR: MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group)
25.07.19DGAP-News: Invitation to MorphoSys Q2 2019 Conference Call on August 7, 2019 (EQS Group)
24.07.19DGAP-PVR: MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group)
09.07.19DGAP-DD: MorphoSys AG english (EQS Group)
08.07.19DGAP-News: MorphoSys and Vivoryon Therapeutics Enter Agreement on Small Molecule Inhibitors of CD47-SIRP alpha Signaling in Immuno-Oncology (EQS Group)
03.07.19DGAP-PVR: MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group)
03.07.19DGAP-News: MorphoSys's Licensing Partner GSK Initiates Phase 3 Clinical Program With Otilimab (MOR103/GSK3196165) in Rheumatoid Arthritis; MorphoSys Updates its Financial Guidance for 2019 (EQS Group)
03.07.19DGAP-Adhoc: Ad hoc: MorphoSys Increases Financial Guidance for 2019 Following a Milestone Payment for Antibody Otilimab (MOR103/GSK3196165) by GSK (EQS Group)
28.06.19DGAP-PVR: MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group)
26.06.19DGAP-PVR: MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group)
24.06.19DGAP-Adhoc: Correction of a release from 24/06/2019, 20:36 CET/CEST - Ad hoc: MorphoSys Appoints Jean-Paul Kress, M.D., as New Chief Executive Officer (EQS Group)
24.06.19DGAP-News: MorphoSys Appoints Jean-Paul Kress, M.D., as New Chief Executive Officer (EQS Group)
24.06.19DGAP-Adhoc: Ad hoc: MorphoSys Appoints Jean-Paul Kress, M.D., as New Chief Executive Officer (EQS Group)
22.06.19DGAP-News: MorphoSys Presents Primary Analysis Data from L-MIND Study of Tafasitamab (MOR208) in combination with Lenalidomide in r/r DLBCL at ICML 2019 (EQS Group)
14.06.19DGAP-PVR: MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group)
14.06.19DGAP-News: MorphoSys's Licensee Janssen Announces Top-line Phase 3 Results for Guselkumab (Tremfya(R)) in Adults with Active Psoriatic Arthritis (EQS Group)
11.06.19DGAP-PVR: MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group)
05.06.19DGAP-PVR: MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group)
05.06.19DGAP-PVR: MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group)
03.06.19DGAP-PVR: MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group)
24.05.19DGAP-PVR: MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group)
23.05.19DGAP-News: MorphoSys to Present at Upcoming Investor Conferences (EQS Group)
22.05.19DGAP-News: MorphoSys AG Reports Outcome of Annual General Meeting 2019 (EQS Group)
16.05.19DGAP-News: MorphoSys AG: Primary Endpoint of L-MIND, a Combination Study of Tafasitamab (MOR208) and Lenalidomide, has been met, Confirming Previously Published Activity (EQS Group)
16.05.19DGAP-Adhoc: MorphoSys AG: Ad hoc: Primary Endpoint of L-MIND, a Combination Study of Tafasitamab (MOR208) and Lenalidomide, has been met, Confirming Previously Published Activity (EQS Group)
14.05.19DGAP-PVR: MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group)
09.05.19DGAP-PVR: MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group)
07.05.19DGAP-News: MorphoSys AG Reports First Quarter 2019 Results (EQS Group)
02.05.19DGAP-News: Invitation to MorphoSys Q1 2019 Conference Call on May 8, 2019 (EQS Group)
29.04.19DGAP-News: MorphoSys and I-Mab Biopharma Announce First Patient Dosed in Phase 3 Clinical Study of MOR202/TJ202 in Multiple Myeloma (EQS Group)
Seite: 123

MorphoSys News

MorphoSys News: auf dieser Seite finden Sie alle MorphoSys News und Nachrichten zur MorphoSys Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch MorphoSys News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um MorphoSys News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.
Werbung
finanzen.net zero
finanzen.net zero

Oskar

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln